Overall, the correlations of PDIA3 and transcripts encoding the extracellular proteins from our data set with DMFS in basal-type breast cancer implicate a clinical relevance to utilizing PDIA3 inhibition to reduce levels of these proteins. This evidence concerns the gene PDIA3 and breast carcinoma.